Search This Blog

Wednesday, August 5, 2026

Immuneering advances Phase 3 MAPKeeper 301 trial

 

Immuneering posts Q2 2026 results with $182.7M cash, runway into 2029, advances Phase 3 MAPKeeper 301 trial

  • Pivotal Phase 3 MAPKeeper 301 study evaluates atebimetinib in first-line treatment of pancreatic cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)